Patents by Inventor Chang-Zheng Chen

Chang-Zheng Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11955070
    Abstract: A first driver circuit is configured to cooperate with a second driver circuit to control a display panel, wherein the first driver circuit is configured to output display data to a first area of the display panel and the second driver circuit is configured to output display data to a second area of the display panel. A method used for the first driver circuit includes outputting at least one emission control signal to control the second area of the display panel when the second driver circuit is disabled.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: April 9, 2024
    Assignee: NOVATEK Microelectronics Corp.
    Inventors: Kun-Zheng Lin, Chang-Hung Chen, Wei-Chieh Lin, Po-Sheng Liao
  • Publication number: 20220332769
    Abstract: Provided herein are multivalent particles and compositions of multivalent particles for blocking viral infection.
    Type: Application
    Filed: June 30, 2022
    Publication date: October 20, 2022
    Inventors: Chang-Zheng Chen, Guoqiang Dong, Yiling Luo, Hua Zhou, Tian-Qiang Sun, Michael Chen
  • Patent number: 11453705
    Abstract: Provided herein are multivalent particles and compositions of multivalent particles for blocking viral infection.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: September 27, 2022
    Assignee: ACHELOIS BIOPHARMA, INC.
    Inventors: Chang-Zheng Chen, Guoqiang Dong, Yiling Luo, Hua Zhou, Tian-Qiang Sun, Michael Chen
  • Publication number: 20220152098
    Abstract: The present invention provides modified antigen-specific immune cells expressing an exogenous CD 160 protein. In some embodiments, the modified antigen-specific immune cell further comprises a functional exogenous receptor, such as an engineered TCR or a CAR. The present invention also provides methods of modulating CD 160 activity in antigen-specific immune cells. The present invention also provides methods and pharmaceutical compositions for cancer treatment using the modified antigen-specific immune cells and the modulators of CD 160 activity described herein.
    Type: Application
    Filed: February 28, 2020
    Publication date: May 19, 2022
    Inventors: Chang-Zheng CHEN, Hua ZHOU, Tian-Qiang SUN, Yiling LUO, Guoqiang DONG
  • Publication number: 20220135626
    Abstract: Provided herein are multivalent particles and compositions of multivalent particles for blocking viral infection.
    Type: Application
    Filed: October 29, 2021
    Publication date: May 5, 2022
    Inventors: Chang-Zheng Chen, Guoqiang Dong, Yiling Luo, Hua Zhou, Tian-Qiang Sun, Michael Chen
  • Publication number: 20210069245
    Abstract: Provided are methods of treating cancer using adoptive cell therapy with T cells modified to have a reduced T cell receptor (TCR) signaling threshold and/or increased TCR sensitivity, and to have improved anti-tumor properties, such as increased cytotoxic activity and reduced susceptibility to immune suppression and/or exhaustion. Also provided are methods of making and compositions comprising such modified T cells.
    Type: Application
    Filed: January 7, 2019
    Publication date: March 11, 2021
    Inventors: Chang-Zheng CHEN, Cordelia YU, Tianqiang SUN, Hanane LAKLAI
  • Patent number: 9598695
    Abstract: MicroRNAs (miRNAs) are a diverse and abundant class of ˜22-nucleotide (nt) endogenous regulatory RNAs that play a variety of roles in animal cells by controlling gene expression at the posttranscriptional level. Increased miR-181a expression in mature T cells is shown to cause a marked increase in T cell activation and augments T cell sensitivity to peptide antigens. Moreover, T cell blasts with higher miR-181a expression become reactive to antagonists. The effects of miR-181a on antigen discrimination are in part achieved by dampening the expression of multiple negative regulators in the T cell receptor (TCR) signaling pathway, including PTPN22 and the dual specificity phosphatases DUSP5 and DUSP6. This results in a reduction in the TCR signaling threshold, thus quantitatively and qualitatively enhancing T cell sensitDynaivity to antigens.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: March 21, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Qi-Jing Li, Chang-Zheng Chen, Mark M. Davis, Jacqueline Chau
  • Publication number: 20160281087
    Abstract: MicroRNAs (miRNAs) are a diverse and abundant class of ˜22-nucleotide (nt) endogenous regulatory RNAs that play a variety of roles in animal cells by controlling gene expression at the posttranscriptional level. Increased miR-181a expression in mature T cells is shown to cause a marked increase in T cell activation and augments T cell sensitivity to peptide antigens. Moreover, T cell blasts with higher miR-181a expression become reactive to antagonists. The effects of miR-181a on antigen discrimination are in part achieved by dampening the expression of multiple negative regulators in the T cell receptor (TCR) signaling pathway, including PTPN22 and the dual specificity phosphatases DUSP5 and DUSP6. This results in a reduction in the TCR signaling threshold, thus quantitatively and qualitatively enhancing T cell sensitivity to antigens.
    Type: Application
    Filed: May 26, 2016
    Publication date: September 29, 2016
    Inventors: Qi-Jing Li, Chang-Zheng Chen, Mark M. Davis, Jacqueline Chau
  • Patent number: 9388466
    Abstract: Modulation of mRNA activity is achieved with precursor miRNAs (ta-RNAs). ta-RNAs, primarily pre-miRNAs and pri-miRNAs, including truncated and mutated ta-RNAs, are employed for modulation of mRNA expression where it is found that pri- and pre-miRNA have activity independently of the presence of functional mature miRNAs. Modification of at least one of the stem and loop of the ta-RNAs to enhance binding of the ta-RNA to the target mRNA is employed. The modification may be enhanced complementarity between the ta-RNA and the target mRNA and/or improved thermodynamic efficiency in binding of the ta-RNA to the target.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: July 12, 2016
    Assignee: Board of Regents of the Leland Stanford Jr Univ
    Inventors: Chang-Zheng Chen, Robin Trujillo, Sibiao Yue
  • Patent number: 9364522
    Abstract: MicroRNAs (miRNAs) are a diverse and abundant class of ˜22-nucleotide (nt) endogenous regulatory RNAs that play a variety of roles in animal cells by controlling gene expression at the posttranscriptional level. Increased miR-181a expression in mature T cells is shown to cause a marked increase in T cell activation and augments T cell sensitivity to peptide antigens. Moreover, T cell blasts with higher miR-181a expression become reactive to antagonists. The effects of miR-181a on antigen discrimination are in part achieved by dampening the expression of multiple negative regulators in the T cell receptor (TCR) signaling pathway, including PTPN22 and the dual specificity phosphatases DUSP5 and DUSP6. This results in a reduction in the TCR signaling threshold, thus quantitatively and qualitatively enhancing T cell sensitivity to antigens.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: June 14, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Qi-Jing Li, Chang-Zheng Chen, Mark M. Davis, Jacqueline Chau
  • Publication number: 20150037798
    Abstract: Modulation of mRNA activity is achieved with precursor miRNAs (ta-RNAs). ta-RNAs, primarily pre-miRNAs and pri-miRNAs, including truncated and mutated ta-RNAs, are employed for modulation of mRNA expression where it is found that pri- and pre-miRNA have activity independently of the presence of functional mature miRNAs. Modification of at least one of the stem and loop of the ta-RNAs to enhance binding of the ta-RNA to the target mRNA is employed. The modification may be enhanced complementarity between the ta-RNA and the target mRNA and/or improved thermodynamic efficiency in binding of the ta-RNA to the target.
    Type: Application
    Filed: August 12, 2014
    Publication date: February 5, 2015
    Inventors: Chang-Zheng Chen, Robin Trujillo, Sibiao Yue
  • Publication number: 20150004186
    Abstract: MicroRNAs (miRNAs) are a diverse and abundant class of ˜22-nucleotide (nt) endogenous regulatory RNAs that play a variety of roles in animal cells by controlling gene expression at the posttranscriptional level. Increased miR-181a expression in mature T cells is shown to cause a marked increase in T cell activation and augments T cell sensitivity to peptide antigens. Moreover, T cell blasts with higher miR-181a expression become reactive to antagonists. The effects of miR-181a on antigen discrimination are in part achieved by dampening the expression of multiple negative regulators in the T cell receptor (TCR) signaling pathway, including PTPN22 and the dual specificity phosphatases DUSP5 and DUSP6. This results in a reduction in the TCR signaling threshold, thus quantitatively and qualitatively enhancing T cell sensitivity to antigens.
    Type: Application
    Filed: May 27, 2014
    Publication date: January 1, 2015
    Inventors: Qi-Jing Li, Chang-Zheng Chen, Mark M. Davis, Jacqueline Chau
  • Patent number: 8841437
    Abstract: Modulation of mRNA activity is achieved with precursor miRNAs (ta-RNAs). ta-RNAs, primarily pre-miRNAs and pri-miRNAs, including truncated and mutated ta-RNAs, are employed for modulation of mRNA expression where it is found that pri- and pre-miRNA have activity independently of the presence of functional mature miRNAs. Modification of at least one of the stem and loop of the ta-RNAs to enhance binding of the ta-RNA to the target mRNA is employed. The modification may be enhanced complementarity between the ta-RNA and the target mRNA and/or improved thermodynamic efficiency in binding of the ta-RNA to the target.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: September 23, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Chang-Zheng Chen, Robin Trujillo, Sibiao Yue
  • Publication number: 20140187613
    Abstract: The invention relates to microRNAs, methods of producing microRNAs and methods for using microRNAs.
    Type: Application
    Filed: November 18, 2013
    Publication date: July 3, 2014
    Applicant: Whitehead Institute for Biomedical Research
    Inventors: Chang-Zheng Chen, David P. Bartel, Harvey Lodish
  • Patent number: 8741860
    Abstract: MicroRNAs (miRNAs) are a diverse and abundant class of ˜22-nucleotide (nt) endogenous regulatory RNAs that play a variety of roles in animal cells by controlling gene expression at the posttranscriptional level. Increased miR-181a expression in mature T cells is shown to cause a marked increase in T cell activation and augments T cell sensitivity to peptide antigens. Moreover, T cell blasts with higher miR-181a expression become reactive to antagonists. The effects of miR-181a on antigen discrimination are in part achieved by dampening the expression of multiple negative regulators in the T cell receptor (TCR) signaling pathway, including PTPN22 and the dual specificity phosphatases DUSP5 and DUSP6. This results in a reduction in the TCR signaling threshold, thus quantitatively and qualitatively enhancing T cell sensitivity to antigens.
    Type: Grant
    Filed: June 2, 2010
    Date of Patent: June 3, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Qi-Jing Li, Chang-Zheng Chen, Mark M. Davis, Jacqueline Chau
  • Patent number: 8609832
    Abstract: The invention relates to microRNAs, methods of producing microRNAs and methods for using microRNAs.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: December 17, 2013
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Chang-Zheng Chen, David P. Bartel, Harvey Lodish
  • Patent number: 8247388
    Abstract: The ability of miR-181a to support active signaling between Notch and pre-TCR pathways by coordinately dampening negative regulators of these pathways allows the use of miR-181a as a therapeutic target for T-ALL.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: August 21, 2012
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Chang-Zheng Chen, Tin Mao
  • Publication number: 20120196924
    Abstract: The invention relates to microRNAs, methods of producing microRNAs and methods for using microRNAs.
    Type: Application
    Filed: December 15, 2011
    Publication date: August 2, 2012
    Applicant: Whitehead Institute for Biomedical Research
    Inventors: Chang-Zheng Chen, David Bartel, Harvey Lodish
  • Patent number: 8106180
    Abstract: The invention relates to microRNAs, methods of producing microRNAs and methods for using microRNAs.
    Type: Grant
    Filed: August 6, 2004
    Date of Patent: January 31, 2012
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Chang-Zheng Chen, David Bartel, Harvey Lodish
  • Publication number: 20110034532
    Abstract: MicroRNAs (miRNAs) are a diverse and abundant class of ˜22-nucleotide (nt) endogenous regulatory RNAs that play a variety of roles in animal cells by controlling gene expression at the posttranscriptional level. Increased miR-181a expression in mature T cells is shown to cause a marked increase in T cell activation and augments T cell sensitivity to peptide antigens. Moreover, T cell blasts with higher miR-181a expression become reactive to antagonists. The effects of miR-181a on antigen discrimination are in part achieved by dampening the expression of multiple negative regulators in the T cell receptor (TCR) signaling pathway, including PTPN22 and the dual specificity phosphatases DUSP5 and DUSP6. This results in a reduction in the TCR signaling threshold, thus quantitatively and qualitatively enhancing T cell sensitivity to antigens.
    Type: Application
    Filed: June 2, 2010
    Publication date: February 10, 2011
    Inventors: QI-JING LI, CHANG-ZHENG CHEN, MARK M. DAVIS, JACQUELINE CHAU